October 17, 2006
Andrew C. von Eschenbach, M.D.
Acting Commissioner U.S Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857-0001
Dear Commissioner Eschenbach:
In light of the recent Los Angeles Times article, "FDA Budget
Malnourished: A study of ADHD drug risks may be halted as the agency
struggles to keep up with demands" (October 7, 2006), CHADD is writing
to urge that this study be completed and published as soon as
CHADD is a family based organization with 14,000 members. Both the
National Institute of Mental Health in its Multi-modal Treatment (MTA)
study on AD/HD and the Surgeon General’s Report on Mental Health
emphasize that the safety and efficacy of medication is of paramount
importance to parents, patients, and doctors alike. Given the highly
publicized accounts of possible cardiac and other health related risks
possibly associated with some medications needed to treat ADHD, we
believe the FDA must complete this study to ensure that any risks are
accurately assessed and the facts discovered and released. Halting this
study could reinforce a growing public concern about effective
treatments for AD/HD while completing the study will allow doctors and
patients and their families to make informed choices about needed and
effective medications for AD/HD.
Thank you for considering our views.
E. Clarke Ross, D.P.A.
4601 Presidents Drive, Suite 300
Lanham, MD 20706
From: CDER DRUG INFO [mailto:DRUGINFO@cder.fda.gov]
Sent: Tuesday, November 07, 2006 2:21 PM
To: Clarke Ross
Subject: Los Angeles Times article
Dear E. Clarke Ross:
On behalf of Dr. Andrew C. von Eschenbach, Acting Commissioner, and the
Center for Drug Evaluation and Research (CDER), I would like to thank
you for making your thoughts known to the Agency regarding the October
7, 2006, Los Angeles Times article entitled "FDA Budget Malnourished: A
study of ADHD drug risks may be halted as the agency struggles to keep
up with demands."
We appreciate your thoughts and suggestions regarding this issue and
will contact you in the future if you can be of assistance.
Thank you again.
Division of Drug Information (HFD-240)
Office of Training and Communications Center for Drug Evaluation and
Research Food and Drug Administration